Bright Minds Biosciences (DRUG) Competitors $36.17 +0.60 (+1.69%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$36.18 +0.02 (+0.04%) As of 03/27/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. NTLA, BGM, RCUS, VIR, RCKT, COLL, XNCR, REPL, PAHC, and DAWNShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Intellia Therapeutics (NTLA), Qilian International Holding Group (BGM), Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT), Collegium Pharmaceutical (COLL), Xencor (XNCR), Replimune Group (REPL), Phibro Animal Health (PAHC), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Intellia Therapeutics Qilian International Holding Group Arcus Biosciences Vir Biotechnology Rocket Pharmaceuticals Collegium Pharmaceutical Xencor Replimune Group Phibro Animal Health Day One Biopharmaceuticals Bright Minds Biosciences (NASDAQ:DRUG) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability. Is DRUG or NTLA more profitable? Bright Minds Biosciences' return on equity of -5.85% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -5.85% -5.68% Intellia Therapeutics N/A -49.34%-40.27% Do institutionals & insiders have more ownership in DRUG or NTLA? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 3.2% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor DRUG or NTLA? In the previous week, Intellia Therapeutics had 35 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 36 mentions for Intellia Therapeutics and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.62 beat Intellia Therapeutics' score of 0.28 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Overall Sentiment Bright Minds Biosciences Very Positive Intellia Therapeutics Neutral Does the MarketBeat Community prefer DRUG or NTLA? Intellia Therapeutics received 437 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. However, 100.00% of users gave Bright Minds Biosciences an outperform vote while only 68.90% of users gave Intellia Therapeutics an outperform vote. CompanyUnderperformOutperformBright Minds BiosciencesOutperform Votes6100.00% Underperform VotesNo VotesIntellia TherapeuticsOutperform Votes44368.90% Underperform Votes20031.10% Do analysts prefer DRUG or NTLA? Bright Minds Biosciences currently has a consensus target price of $84.33, suggesting a potential upside of 133.16%. Intellia Therapeutics has a consensus target price of $37.56, suggesting a potential upside of 347.09%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.63 Which has better earnings & valuation, DRUG or NTLA? Bright Minds Biosciences has higher earnings, but lower revenue than Intellia Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.17-212.76Intellia Therapeutics$57.88M15.02-$481.19M-$5.25-1.60 Which has more volatility & risk, DRUG or NTLA? Bright Minds Biosciences has a beta of -6.45, suggesting that its share price is 745% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. SummaryBright Minds Biosciences and Intellia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$254.78M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-212.757.2023.1419.03Price / SalesN/A226.01384.1193.17Price / CashN/A65.6738.1634.64Price / Book6.176.476.954.33Net Income-$2.06M$141.90M$3.20B$247.06M7 Day Performance2.90%-3.20%-2.28%-0.37%1 Month Performance-2.87%-5.64%2.88%-3.85%1 Year Performance2,914.42%-7.47%10.87%1.27% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences2.7387 of 5 stars$36.17+1.7%$84.33+133.2%+2,991.5%$254.78MN/A-212.75N/APositive NewsNTLAIntellia Therapeutics4.4793 of 5 stars$9.58+4.8%$37.56+292.0%-68.9%$991.69M$57.88M-1.76600Analyst RevisionBGMQilian International Holding GroupN/A$10.03+4.5%N/AN/A$975.14M$25.10M0.00298Positive NewsGap UpRCUSArcus Biosciences2.507 of 5 stars$9.15-2.0%$30.25+230.5%-53.5%$962.43M$258M-2.91500VIRVir Biotechnology3.6051 of 5 stars$7.01-2.0%$35.67+408.8%-34.0%$961.37M$63.71M-1.79580RCKTRocket Pharmaceuticals4.6678 of 5 stars$8.83+0.8%$43.00+387.0%-71.1%$941.54MN/A-3.21240Positive NewsCOLLCollegium Pharmaceutical4.0759 of 5 stars$29.67+0.7%$43.60+46.9%-27.7%$934.19M$631.45M12.79210Analyst RevisionXNCRXencor3.4825 of 5 stars$12.98+1.7%$34.38+164.8%-48.7%$914.60M$110.49M-4.06280REPLReplimune Group3.8551 of 5 stars$11.78+1.0%$19.43+64.9%+26.7%$907.24MN/A-3.84210Positive NewsPAHCPhibro Animal Health3.9549 of 5 stars$21.85+2.8%$21.00-3.9%+66.0%$884.99M$1.11B45.521,860Analyst DowngradeShort Interest ↓Positive NewsDAWNDay One Biopharmaceuticals2.8166 of 5 stars$8.67+6.8%$34.57+298.7%-48.1%$878.75M$131.16M-8.4260Analyst Forecast Remove Ads Related Companies and Tools Related Companies Intellia Therapeutics Competitors Qilian International Holding Group Competitors Arcus Biosciences Competitors Vir Biotechnology Competitors Rocket Pharmaceuticals Competitors Collegium Pharmaceutical Competitors Xencor Competitors Replimune Group Competitors Phibro Animal Health Competitors Day One Biopharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRUG Stock Free DRUG Stock Alerts